Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report

Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Aakriti, Zaemes, Jacob, Ozdemirli, Metin, Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046803/
https://www.ncbi.nlm.nih.gov/pubmed/36998440
http://dx.doi.org/10.3389/fonc.2023.1134151
_version_ 1785013764561567744
author Arora, Aakriti
Zaemes, Jacob
Ozdemirli, Metin
Kim, Chul
author_facet Arora, Aakriti
Zaemes, Jacob
Ozdemirli, Metin
Kim, Chul
author_sort Arora, Aakriti
collection PubMed
description Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B–RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment.
format Online
Article
Text
id pubmed-10046803
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100468032023-03-29 Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report Arora, Aakriti Zaemes, Jacob Ozdemirli, Metin Kim, Chul Front Oncol Oncology Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B–RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10046803/ /pubmed/36998440 http://dx.doi.org/10.3389/fonc.2023.1134151 Text en Copyright © 2023 Arora, Zaemes, Ozdemirli and Kim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Arora, Aakriti
Zaemes, Jacob
Ozdemirli, Metin
Kim, Chul
Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
title Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
title_full Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
title_fullStr Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
title_full_unstemmed Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
title_short Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
title_sort response to selpercatinib in a patient with ret fusion-positive pulmonary large-cell neuroendocrine carcinoma: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046803/
https://www.ncbi.nlm.nih.gov/pubmed/36998440
http://dx.doi.org/10.3389/fonc.2023.1134151
work_keys_str_mv AT aroraaakriti responsetoselpercatinibinapatientwithretfusionpositivepulmonarylargecellneuroendocrinecarcinomaacasereport
AT zaemesjacob responsetoselpercatinibinapatientwithretfusionpositivepulmonarylargecellneuroendocrinecarcinomaacasereport
AT ozdemirlimetin responsetoselpercatinibinapatientwithretfusionpositivepulmonarylargecellneuroendocrinecarcinomaacasereport
AT kimchul responsetoselpercatinibinapatientwithretfusionpositivepulmonarylargecellneuroendocrinecarcinomaacasereport

Ejemplares similares